目的:比较根据两种不同指南治疗的急性淋巴细胞白血病患者的诱导缓解结果。
方法:描述性回顾性队列研究在拉合尔儿童医院进行,巴基斯坦,包括2014年9月至2015年8月急性淋巴细胞白血病患者的临床信息表.有关人口统计的数据,风险分类,我们分别收集了采用拉合尔方案治疗的第1组患者和采用英国急性淋巴细胞白血病-2011临时指南治疗的第2组患者的快速早期应答和诱导-缓解评估.使用SPSS20.0版分析数据。
结果:在中位年龄为6.4岁(四分位距:1.5-16岁)的98例患者中,48(49%)在第1组中,50(51%)在第2组中。第1组中有14例(29%)具有标准风险的患者,而34例(71%)是高风险的。第2组中的相应数字为30(60%)和第2组中的20(40%)。在第1组中的18名(37.5%)患者和第2组中的11名(28%)患者中发现了快速的早期反应。第1组38例(79%)患者和第2组36例(72%)患者获得缓解。在第2组中,快速早期反应与诱导缓解之间存在显着关联(p<0.05),而在第1组中则没有关联(p>0.05)。
结论:两个治疗组的诱导缓解率相当,但仅在使用英国急性淋巴细胞白血病-2011临时指南治疗的患者中观察到快速早期应答与诱导-缓解显著相关.
OBJECTIVE: To compare the outcome of induction-remission in acute lymphoblastic leukaemia patients treated according to two different
guidelines.
METHODS: The descriptive retrospective cohort study was conducted at The Children\'s Hospital Lahore, Pakistan, and comprised clinical information sheets of acute lymphoblastic leukaemia patients from September 2014 to August 2015. Data regarding demographics, risk categorisation, rapid early response and induction-remission assessment was collected separately for Group 1 patients treated with Lahore protocol and Group 2 patients using United Kingdom acute lymphoblastic leukaemia-2011 interim
guidelines. Data was analysed using SPSS version 20.0.
RESULTS: Of the 98 patients who had a median age of 6.4 years (interquartile range: 1.5-16 years), 48(49%) were in Group 1 and 50(51%) in Group 2. There were 14(29%) patients with standard risk in Group 1 while 34(71%) were high-risk. The corresponding numbers in Group 2 were 30(60%) and 20(40%) in Group 2. Rapid early response was noted in 18(37.5%) patients in Group 1 and 11(28%) in Group 2. Remission was achieved in 38(79%) patients in Group 1 and 36(72%) in Group 2. There was significant association of rapid early response with induction-remission in Group 2 (p<0.05) but not in Group 1 (p>0.05).
CONCLUSIONS: Induction-remission rate was comparable in the two treatment groups, but significant association of rapid early response with induction-remission was observed only in patients treated using United Kingdom acute lymphoblastic leukaemia-2011 interim
guidelines.